Allergic rhinitis (hay fever) mechanism
Hay fever is IgE-mediated Type I hypersensitivity — the same immune pathway as allergic asthma and atopic dermatitis, manifesting in nasal mucosa:
- Sensitisation: on first exposure to pollen, grass, or dust mite allergen, dendritic cells present antigen to T cells in a Th2-biasing context. Allergen-specific IgE is produced and binds nasal mast cells.
- Early-phase: re-exposure cross-links mast cell-bound IgE — degranulation releases histamine, tryptase, and LTC4, causing sneezing, itching, and watery rhinorrhea within minutes.
- Late-phase (4–8 hours): Th2 cytokines (IL-4, IL-5, IL-13) recruit eosinophils to nasal mucosa, causing persistent congestion, mucosal swelling, and post-nasal drip.
The key RCT: Cingi et al. (2008)
A double-blind, placebo-controlled trial in 150 patients with allergic rhinitis compared spirulina (2 g/day) vs placebo for 16 weeks.
Results in the spirulina arm:
- Significant improvement in nasal obstruction, rhinorrhea, sneezing, and nasal itching (all four primary symptom scores)
- Total IgE levels reduced significantly vs placebo
- IL-4 levels reduced significantly — the primary cytokine driving IgE production and Th2 commitment
- No significant side effects compared to placebo group
This is the best-powered human RCT for any supplement in allergic rhinitis — more methodologically rigorous than most supplement trials in this area.
Mechanism: Th1/Th2 rebalancing and IgE reduction
Spirulina reduces IL-4 — this is the mechanism that connects to symptom improvement:
- IL-4 drives B cell class-switching to IgE production. Reducing IL-4 directly reduces ongoing IgE synthesis.
- Spirulina polysaccharides stimulate dendritic cell IL-12 production, pushing T cell polarisation toward Th1 (IFN-γ) and reducing Th2 (IL-4, IL-5, IL-13) dominance.
- This Th1/Th2 rebalancing is the same mechanism exploited in allergen immunotherapy (allergy shots/sublingual drops) — spirulina achieves a partial version of the same immune modulation.
The reduction in IgE explains why mast cell degranulation is reduced — lower IgE on mast cells means less cross-linking per allergen exposure, less histamine release, milder symptoms.
Seasonal vs perennial rhinitis
The Cingi trial was conducted in patients with diagnosed perennial (year-round) rhinitis — predominantly house dust mite sensitisation. Seasonal hay fever (pollen allergy) follows the same mechanism.
For seasonal hay fever, start spirulina 4–8 weeks before pollen season. The IgE reduction and Th1/Th2 rebalancing take weeks to establish — beginning in the acute pollen season is less effective than building the immune shift in advance.
Comparison with antihistamines
Antihistamines (loratadine, cetirizine) block histamine H1 receptors after mast cell degranulation — symptom relief is rapid but the underlying IgE sensitisation is unchanged. Spirulina acts upstream — reducing IgE and Th2 cytokines that drive the sensitisation. These are complementary approaches:
- Spirulina: slow-onset (weeks), addresses root mechanism, reduces severity of reactions
- Antihistamines: fast onset (hours), symptom relief only, no effect on sensitisation
- Combined use is appropriate — spirulina to reduce overall sensitisation burden, antihistamine on high-pollen days for acute symptom control
Comparison with nasal corticosteroids
Nasal corticosteroids (fluticasone, mometasone, budesonide) are the most effective hay fever treatment — they reduce nasal eosinophilic inflammation, mucus production, and late-phase congestion more effectively than any supplement. Spirulina should not replace nasal steroids in moderate-severe hay fever. It can complement them in mild-moderate cases or serve as a non-pharmaceutical option for those who prefer to avoid steroids.
Practical protocol
- Dose: 2 g/day (the trial dose) is the minimum; 5–8 g/day is the range used for broader health benefits and likely provides comparable or greater IgE-reducing effect
- Start time:4–8 weeks before your typical pollen season onset. For the UK, tree pollen starts March/April — begin spirulina in February.
- Continue through season:The IgE reduction needs maintenance — sustained daily intake for the duration of the season.
- Alongside standard treatment:Antihistamines on high-symptom days, nasal steroids if needed — spirulina is an adjunct, not a first-line hay fever treatment
Other Th2-mediated conditions
The same mechanism applies across all Th2-dominant allergic conditions. The evidence is strongest for allergic rhinitis (the RCT), but the mechanism predicts benefit in:
- Atopic dermatitis (eczema)
- Allergic conjunctivitis
- Allergic asthma
- Food allergy sensitisation (secondary prevention)
None of these have dedicated spirulina RCTs — the allergic rhinitis evidence provides the mechanistic and clinical anchor for the broader Th2 claim.